New hope for Hard-to-Treat lymphoma? early trial of ABBV-291 begins
NCT ID NCT06667687
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part worldwide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center /ID# 267471
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Carolina BioOncology Institute /ID# 265259
COMPLETEDHuntersville, North Carolina, 28078, United States
-
Hadassah Medical Center-Hebrew University /ID# 261658
RECRUITINGJerusalem, Jerusalem, 91120, Israel
-
National Cancer Center Hospital East /ID# 261775
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
START Mountain Region /ID# 267592
COMPLETEDWest Valley City, Utah, 84119-3602, United States
-
Sir Charles Gairdner Hospital /ID# 268579
RECRUITINGNedlands, Western Australia, 6009, Australia
-
St Vincent's Hospital Melbourne /ID# 261664
RECRUITINGFitzroy Melbourne, Victoria, 3065, Australia
-
Tel Aviv Sourasky Medical Center /ID# 261659
RECRUITINGTel Aviv, Tel Aviv, 6423906, Israel
-
Texas Oncology - Central/South Texas /ID# 270946
RECRUITINGAustin, Texas, 78705, United States
-
The Cancer Institute Hospital Of JFCR /ID# 267470
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The Christie /ID# 267177
RECRUITINGManchester, M20 4BX, United Kingdom
-
University Hospitals Plymouth NHS Trust /ID# 267174
RECRUITINGPlymouth, PL6 5FP, United Kingdom
-
Virginia Cancer Specialists - Fairfax /ID# 265082
COMPLETEDFairfax, Virginia, 22031, United States
-
Willamette Valley Cancer Institute and Research Center /ID# 270945
RECRUITINGEugene, Oregon, 97401, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-291 (given as an intravenous infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with Non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is also a small study, so results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.